Company* (Country; Symbol)

Company* (Country; Symbol)

Type/Product Area

Terms/Details (Date)


Althea Technologies Inc.*

GeoVax Labs Inc. (OTC BB:GOVX)

Agreement for Althea to manufacture GeoVax's HIV-1 DNA AIDS vaccine

The vaccine will be used in GeoVax's advanced Phase II human trials planned to start in early 2008 (6/20)

BioMerieux SA (France; PARIS:BIM)

AdvanDx Inc.*

Exclusive agreement for U.S. distribution of AdvanDx's PNA FISH diagnostic tests

The tests rapidly identify bacteria and yeast in the blood (5/23)

CyDex Inc.*

Critical Therapeutics Inc. (CRTX)

License and supply agreement granting exclusive worldwide rights to CyDex's Captisol-enabling technology

Critical Therapeutics will develop an injectable formulation of zileuton (6/12)

Genomic Health Inc. (GHDX)

Medical Solutions plc (UK; LSE:MLS)

Exclusive agreement to distribute Genomic Health's Oncotype DX breast cancer assay in the UK

Further details were not disclosed (6/1)

Grant Life Sciences Inc. (OTC BB:GLIFE)

Alphagenics Diaco Biotechnologies Srl* (Italy)

Agreement under which Grant will get rights to Alphagenics' molecular diagnostic test for human papillomaviruses

Grant will have exclusive manufacturing and marketing rights in China and the U.S., and nonexclusive rights in Europe, India, Australia and Japan (6/13)

Laboratory Corp. of America Holdings (NYSE:LH)

Veridex LLC*

License agreement to commercialize nucleic acid testing technology for detecting the presence of a tissue marker in prostate cancer, methylated GST-Pi

LabCorp said it was the first full-service national clinical laboratory in the U.S. to license the technology; terms were not disclosed (5/29)

OncoMethylome Sciences SA (Belgium; BR:ONCOB)

Exact Sciences Corp. (EXAS)

Agreements to advance the commercialization of stool-based colorectal cancer screening technologies through laboratories in Europe and North America

Exact granted nonexclusive rights to its DNA stabilization, isolation and extraction technology; OncoMethylome agreed to pay royalties on sales (6/12)

ProNAi Therapeutics Inc.*

Polymun Scientific GmbH* (Austria)

Agreement to manufacture ProNAi's PNT2258 DNAi- based cancer therapeutic

Polymun will use its cross-flow injector technology to manufacture ProNAi's liposome-formulated lead drug candidate (6/14)

Qiagen NV (QGEN) systems

Biomatrica Inc.*

License and marketing agreement for the exclusive distribution of room temperature DNA storage technology for biological sample storage and sample management

Biomatrica's SampleMatrix technology and Qiagen's rights are expected to be expanded for uses including the stabilization, shipping and storage of DNA molecules in blood and buccal swab samples (5/31)

Sloning Biotechnology* (Germany)

Microsynth AG* (Switzerland)

Distribution partnership for Microsynth to exclusively market and sell Sloning's gene synthesis service, Slonomics, in Switzerland

It also will sell the product family of mutant libraries, Slonomax (6/1)


Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

BR = Brussels Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.